BEDMINSTER, N.J.--(BUSINESS WIRE)--NPS Pharmaceuticals, Inc. (NASDAQ: NPSP), a specialty pharmaceutical company developing orphan therapeutics for rare gastrointestinal and endocrine disorders, today announced that it has completed the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for GATTEX® (teduglutide). NPS has also asked the FDA to designate the application for Priority Review, which is given to drugs that may offer major advances in treatment or provide a treatment where no adequate therapy exists. GATTEX is a novel, recombinant analog of human glucagon-like peptide 2, a peptide involved in gastrointestinal regeneration and repair, which NPS has been developing for the treatment of adults with short bowel syndrome or SBS, a highly disabling and potentially life-threatening chronic disorder.
